Nivolumab vs Warfarin
Nivolumab vs Warfarin: Overview
This comparison examines the pharmacological differences between Nivolumab and Warfarin.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Warfarin: Inhibits vitamin K epoxide reductase complex.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Warfarin — 20-60 hours.
Chemical Properties
Molecular Formula: Warfarin — C19H16O4.
Molecular Weight: Warfarin — 308.3280 g/mol.
Type: Nivolumab — Antibody; Warfarin — Small molecule.